AXLRx Book a callCommission
Twenty minutes with a consultant, before anything is commissioned.Book a scoping call →

Sneha

Senior Analyst · Metabolic · Oncology · Rare Disease · Immunology · Pulmonology

S

Sneha is a Senior Analyst at AXLRx, leading competitive-intelligence and payer & HTA briefs. She frames the commercial question a launch or brand team needs answered and reviews each report against the verify-or-drop standard, so every figure traces to a live regulatory, clinical, or payer source. Her focus spans rare disease, specialty, and market access.

Analyses reviewed (79)

CI · US US MASH Competitive Intelligence Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window. P&HTA · US US NSCLC Payer & HTA CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%. But PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers. P&HTA · US US PNH Payer & HTA Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing. CI · US US ATTR Amyloidosis Competitive Intelligence Tafamidis's ATTR-CM monopoly meets acoramidis — while the orphan-drug exclusion keeps the stabilizer class out of IRA price negotiation. P&HTA · US US Hereditary Angioedema Payer & HTA Specialty-tier prior authorization, prophylaxis above $300K/patient/yr, ICER 2018/2021 value-based benchmarks and no-concurrent-acute-agent rules. P&HTA · US US Myasthenia Gravis Payer & HTA ICER priced efgartigimod's value at $18,300–28,400 a year, under half its ~$418,400 launch cost. That gap is hardening into a three-tier FcRn-to-C5 step-edit across US commercial plans. P&HTA · US US Spinal Muscular Atrophy Payer & HTA Zolgensma's $2.125M one-time cost, outcomes-based Medicaid contracts, and Part B vs Part D routing across three SMA modalities. DL · US US Spinal Muscular Atrophy Disease Landscape SMN1/SMN2 biology, the Type 1–4 severity spectrum, and how newborn screening splits SMA into pre-symptomatic and symptomatic populations. CI · US US Sickle Cell Disease Competitive Intelligence Two Dec-2023 gene therapies (Casgevy, Lyfgenia) reset a ~100,000-patient market, while voxelotor's 2024 withdrawal thins the oral field. P&HTA · US US Dravet Syndrome Payer & HTA Fintepla's list price runs roughly 3x Epidiolex, and payer scrutiny turns on high WAC against a small, severe paediatric population. CI · US US Cold Agglutinin Disease Competitive Intelligence Sutimlimab (Enjaymo) is the only FDA-approved CAD therapy — competing against off-label rituximab-based standard of care, not a branded rival. DL · US US Atopic Dermatitis Disease Landscape US atopic dermatitis epidemiology — 16.5M adults, the moderate-to-severe pool, and the atopic march that frames the biologic-eligible segment. P&HTA · US US Type 2 Diabetes Payer & HTA Type 2 Diabetes is IRA ground zero: three orals negotiated for 2026, semaglutide at $274 for 2027, and the class price anchor reset. P&HTA · US US Obesity Payer & HTA Medicare covers Wegovy only for cardiovascular risk, not obesity alone. The IRA's IPAY 2027 semaglutide price applies across the franchise, and ICER returned a 2025 'high value' verdict. CI · US US Plaque Psoriasis Competitive Intelligence Six mechanisms now compete for moderate-to-severe plaque psoriasis in the US, and the efficacy bar has moved from PASI 75 to PASI 90. IL-17A, dual IL-17A/F, IL-23p19, IL-12/23, TNF and oral TYK2 all hold ground. DL · US US Breast Cancer HR+/HER2- Disease Landscape HR+/HER2- is the largest breast cancer subtype, roughly 68% of the estimated 317,000 new US invasive female cases in 2025. Most present early and are curable, but 20-30% recur to metastatic disease where five-year survival falls to about a third, making biomarker testing (ESR1, PIK3CA) the fork that determines the treatment path. CI · GCC GCC PNH Competitive Intelligence Anti-C5 IV therapy holds the GCC PNH market under NPHC and MOH specialist-centre gating. Iptacopan's 82.3% haemoglobin-response rate has not reached a single GCC formulary. CI · GCC GCC Dravet Syndrome Competitive Intelligence GCC Dravet prescribing runs opposite the US and EU hierarchy. Cannabidiol is de-facto inaccessible under narcotics law, so stiripentol is the specialist standard of care. CI · UK UK Dravet Syndrome Competitive Intelligence Cannabidiol and fenfluramine anchor the NHS-commissioned NICE algorithm; stiripentol still holds a backbone role. New entrants must beat an entrenched three-drug sequence, not just show efficacy. MSM · US US Myasthenia Gravis Market Sizing Model US gMG prevalence runs 100,000-200,000, but only 4,000-6,000 patients are on FcRn therapy today. 1,200-2,100 of those remain inadequately controlled. The near-term opportunity is the funnel gap, not the epidemiology total. CI · GCC GCC Myasthenia Gravis Competitive Intelligence NPHC formulary criteria for the FcRn class don't yet exist, so pyridostigmine and steroids still treat 85%+ of GCC patients. Efgartigimod reached GCC neurology centres via SFDA and MOH UAE registration in 2023. MSM · GCC GCC Sickle Cell Disease Market Sizing Model Carrier-rate-adjusted epidemiology implies 140,000-200,000 KSA sickle cell patients. NPHC's structured active-management programme reaches only 8,000-10,000 — a care-registration gap, not a measurement error. MSM · GCC GCC Pompe Disease Market Sizing Model Total GCC Pompe prevalence runs 400-600, consanguinity-elevated. 200-300 are actively managed on ERT, and NPHC's formulary budget centers on a narrower 80-120 long-term-stable core within that population. MSM · US US Spinal Muscular Atrophy Market Sizing Model US SMA sizing splits into two live populations, not one number. 8,000-10,000 prevalent patients across Types 1-4, and a separate 500-700-patient Zolgensma-treated cohort now aging into a monitoring window where 15-20% show early motor plateau. MSM · US US Hereditary Angioedema Market Sizing Model An estimated 8,000-9,000 Americans have HAE, and only 35-40% receive any prophylaxis. That leaves 2,500-4,000 attack-eligible patients never treated, a pool nearly as large as the entire treated population. LR · UK UK Pompe Disease Launch Readiness An ADA-positive-specific NICE case beats competing on incremental FVC improvement against alglucosidase. The 80-120 NIV-dependent LOPD patients are the highest-urgency target, and the BIMDG partnership shapes NICE's evidence bar. LR · US US COPD Launch Readiness Ensifentrine and dupilumab, both approved in 2024, already own the exacerbator add-on tier. A new entrant must clear a 31-41% exacerbation-reduction bar and pick a phenotype-agnostic or eosinophil-gated lane before it competes on anything else. LR · US US Hereditary Angioedema Launch Readiness Binding constraint: grow the never-prophylaxed cohort before donidalorsen resets the oral efficacy bar — not switch stable lanadelumab patients. PFM · GCC GCC Myasthenia Gravis Patient Flow Model 6,000-10,000 GCC gMG patients on the epidemiology estimate, of whom 200-300 are refractory and fewer than 50 are currently on biologic therapy. PFM · UK UK Sickle Cell Disease Patient Flow Model Newborn screening has been universal since 1999, so the UK's 15,000-17,000 diagnosed sickle cell patients are counted with confidence. They narrow to a 4,000-6,000-patient conventional-therapy gap and a separate 200-300-per-year gene-therapy-eligible pool. LR · UK UK IgA Nephropathy Launch Readiness NICE will reject any IgAN submission not built on eGFR slope with mandatory SGLT2i background. This sizes the 3,000-5,000 UK patients eligible for a novel agent and the ESRD-delay cost model that clears the QALY bar. PSM · DE DE PNH Pricing Strategy Model Iptacopan's substantial-benefit finding gave Germany real negotiating leverage over Novartis. Six months on, no negotiated net price has surfaced in the Lauer-Taxe — the pricing signal this model is built to catch before a launch-sequencing decision locks in the wrong assumption. DL · UK UK Pompe Disease Disease Landscape A ~25% inadequate-ERT-responder subset defines the next-generation enzyme-replacement opportunity in UK Pompe. The UK Pompe Consortium's shared-care network sits against a 3–8 year late-onset diagnostic delay. LR · US US Breast Cancer HR+/HER2- Launch Readiness The post-CDK4/6 line in HR+/HER2- metastatic breast cancer is fragmented by biomarker. Elacestrant's own cost-effectiveness analysis found it 58 times above the standard willingness-to-pay threshold. That precedent is the bar a new targeted entrant must clear. PFM · GCC GCC Dravet Syndrome Patient Flow Model 600-800 estimated GCC Dravet patients, fewer than 200 SCN1A-confirmed. A 200-400 near-term addressable cohort sits within that confirmed subset. P&HTA · UK UK Spinal Muscular Atrophy Payer & HTA All three funded SMA therapies in England reached the NHS through a conditional route. Zolgensma was recommended under HST15 and extended under HST24; nusinersen and risdiplam spent seven years in managed access before TA1162 moved them to routine commissioning. DL · GCC GCC Dravet Syndrome Disease Landscape SCN1A molecular confirmation gap, the cannabidiol regulatory restriction, and the stiripentol-backbone standard of care across GCC paediatric neurology. P&HTA · UK UK Pompe Disease Payer & HTA NHS England's Pompe commissioning policy defines a 45-50 patient switch-eligible cohort for avalglucosidase alfa (NICE TA821). That is a manageable NHS budget event; broader first-line uptake would be a materially larger one. KOL · GCC GCC Dravet Syndrome KOL Mapping A five-institution Saudi consortium across Riyadh, Jeddah and Dammam tracked 44 Dravet patients on stiripentol combination therapy. That kind of coordinated, cross-city publication is exactly the institutional signal this workbook sizes before any individual name enters it. DL · FR FR PNH Disease Landscape France's national hospitalisation database puts PNH prevalence near 1 in 94,000, or 897 patients from 2018 to 2022. That is lower than the 16-per-million figure Germany's DGHO Onkopedia guideline borrows from French and UK registries. DL · UK UK ATTR Amyloidosis Disease Landscape Vutrisiran's TA868 PAS-backed approval is reshaping UK ATTR identification and treatment. It joins NICE-recommended tafamidis (TA984, June 2024, after the 2021 TA696 rejection) and a 30-centre Tc-PYP diagnostic pathway. DL · GCC GCC Pompe Disease Disease Landscape The ERT infusion access gap across GCC metabolic centres defines the Pompe opportunity. Newborn screening is expanding for infantile-onset disease, while late-onset still takes a limb-girdle diagnostic detour. MSM · US US Dravet Syndrome Market Sizing Model US Dravet incidence of 1 in 15,700 births is consistent with the Dravet Syndrome Foundation's 6,000-8,000 prevalence estimate. Only 35-40% of that population, 1,400-2,000 patients, remains inadequately controlled on today's two branded agents. MSM · GCC GCC Spinal Muscular Atrophy Market Sizing Model GCC SMA incidence runs 1:6,000-8,000 against a global 1:10,000. Newborn-screening coverage splitting 90%/85%/75% across KSA, UAE and Qatar means the addressable near-term population depends on which country's screening curve a launch model assumes. PFM · GCC GCC Fabry Disease Patient Flow Model GCC male Fabry prevalence runs 1:20,000-30,000, elevated by founder mutations. Only 200-300 patients are diagnosed against a true burden estimated 3-5 times higher, and female diagnosis lags at under half the male rate. PFM · GCC GCC Spinal Muscular Atrophy Patient Flow Model GCC SMA incidence runs 1:6,000-8,000 births, with newborn-screening coverage from 90% down to under 50%. An 800-1,200-patient legacy Type 2/3 pool and a 60-80/yr Zolgensma cohort anchor the on-therapy view. PFM · GCC GCC ATTR Amyloidosis Patient Flow Model Two GCC ATTR-CM burden estimates both convert to fewer than 1,000 confirmed diagnoses. One puts the range at 15,000-25,000, the other at a narrower 2,000-5,000 ATTRwt-CM cohort. This model reconciles the gap and traces it to scintigraphy access. LR · GCC GCC PNH Launch Readiness First-mover oral complement inhibition in GCC PNH is a closing window. SFDA registration ahead of iptacopan, not competitive differentiation from entrenched anti-C5, decides commercial success. DL · GCC GCC Sickle Cell Disease Disease Landscape Premarital screening impact, the adult transition care gap, and the gene therapy access horizon across one of the world's highest per-capita SCD burdens. LR · GCC GCC Myasthenia Gravis Launch Readiness Refractory gMG in the GCC is a 200-300 patient market concentrated at fewer than 15 named neurologists. The constraint is building a specialist key-account relationship, not clinical proof. CI · UK UK PNH Competitive Intelligence All three UK PNH agents cleared NICE via the standard Technology Appraisal route, not the ultra-rare one. Ravulizumab (TA698), iptacopan (TA1000) and crovalimab all took it. Convenience and switch dynamics, not pathway-driven affordability, now determine NHS share. LR · UK UK Dravet Syndrome Launch Readiness 600-900 UK Dravet patients remain uncontrolled on CBD plus fenfluramine. This weighs the cardiac-monitoring burden a REMS-free agent could remove against the soticlestat clock competing for the same refractory population. LR · UK UK ATTR Amyloidosis Launch Readiness Any new ATTR-CM entrant is judged against tafamidis on NICE's TA984 QALY bar, now joined by acoramidis's TA1121 recommendation. The diagnosis pipeline still leaves 15,000-36,000 UK patients undiagnosed, and the National Amyloidosis Centre is the single investment that decides the outcome. MSM · DE DE PNH Market Sizing Model Germany's DGHO Onkopedia guideline states plainly that Germany-specific PNH prevalence and incidence figures do not exist. It borrows 16 cases and 1.3 new diagnoses per million annually from British and French registries, and routes all case-finding through just two national centres, Ulm and Essen. KOL · UK UK Breast Cancer HR+/HER2- KOL Mapping A single five-centre South West England consortium tracks 666 UK patients across all three approved CDK4/6 inhibitors. That kind of coordinated, multi-centre evidence generation is exactly the institutional signal this workbook sizes before any individual name enters it. PFM · GCC GCC PNH Patient Flow Model An estimated 2,000-3,000 Gulf patients carry a clinically significant PNH clone. Only about 400 are confirmed in national registries, and just 150-250 reach complement-inhibitor therapy. Diagnostic capacity, not drug access, is the constraint this model sizes. HTA · UK UK Pompe Disease HTA Strategy Model NICE accepts a £100,000-300,000 QALY threshold for ultra-rare Pompe disease, five to fifteen times the standard appraisal bar. That Highly Specialised Technologies ceiling is what avalglucosidase alfa's TA821 recommendation used, but only with a substantial confidential commercial arrangement. A new entrant without that leverage should build a standalone case for the antibody-positive inadequate-responder subgroup instead. MSM · GCC GCC Dravet Syndrome Market Sizing Model GCC Dravet prevalence is estimated at 600-800 patients, but fewer than 200 are molecularly SCN1A-confirmed. The 200-400 figure used in launch planning is a distinct near-term actionable tier, not a fourth competing total. PFM · UK UK IgA Nephropathy Patient Flow Model 10,000-15,000 UK IgA nephropathy patients, of whom approximately 8,000 are tracked in the UK Renal Registry. Only 3,000-5,000 clear the mandatory ACEi/ARB and SGLT2i optimisation gate to become eligible for a novel agent, and fewer than 500 currently access one pre-NICE. PSM · US US Obesity Pricing Strategy Model Wegovy lists at roughly $1,349 a month, but CMS pays $274 for a 30-day semaglutide supply from 2027. That 71% cut applies to Ozempic, Rybelsus and Wegovy alike. Tirzepatide sits outside the negotiation entirely, for now. PSM · US US Type 2 Diabetes Pricing Strategy Model Two IRA negotiation cycles have now cut across the T2D formulary. Januvia down 79% to $113, Jardiance down 66% to $197, Farxiga down 68% to $178 from January 2026, and semaglutide down 71% to $274, with Janumet and Tradjenta added for 2027. MSM · UK UK Dravet Syndrome Market Sizing Model The UK's NICE-commissioned Dravet algorithm manages an estimated 2,000-2,500 patients on cannabidiol and fenfluramine. The NHS genetic testing registry logs only 400-500 molecularly SCN1A-confirmed cases — a registry-scope gap, not a population contradiction. LR · US US Pompe Disease Launch Readiness 375–600 US LOPD patients are failing next-gen ERT — ADA superiority and first-line labeling decide who can reach them. MSM · UK UK PNH Market Sizing Model The Leeds National PNH Registry tracks about 600 UK patients on complement-inhibitor therapy. A broader estimate cited in AXLRx's own Launch Readiness research puts it near 1,500 total patients and 1,000 treated. Reconciling which count anchors a sizing model is the open question. DL · UK UK Fabry Disease Disease Landscape An estimated 800-patient UK Fabry cohort has both NHS-commissioned ERT and NICE HST4-recommended oral chaperone therapy. The NHS lysosomal-storage-disorder specialist network and UK Fabry Outcome Survey longitudinal data track it. MSM · US US Gaucher Disease Market Sizing Model 6,000 US Type 1 Gaucher patients size a market near $1.8 billion at ERT pricing. That MedlinePlus-sourced population sits inside a genetic sub-segment where Ashkenazi carrier frequency runs 1 in 12-15, against a general-population disease frequency of just 0.70-1.75 per 100,000. MSM · GCC GCC Hereditary Angioedema Market Sizing Model Epidemiology implies 1,200-1,500 true GCC HAE patients, but the KFSH&RC registry confirms fewer than 200. A separate planning estimate used for launch work lands at 400-600 — three numbers, one diagnostic-capacity story. PSM · GCC GCC IgA Nephropathy Pricing Strategy Model IgA nephropathy sits outside NPHC's genetic/orphan disease scope entirely, so there is no GCC formulary price to model. Budesonide clears case-by-case at SAR 80,000-120,000/year through hospital committees or private insurance; sparsentan is not yet tender-priced at all. MSM · US US PNH Market Sizing Model US PNH prevalence spans 15,000 to 20,000 patients across three phenotypes, but only about 3,500 are on complement-inhibitor therapy. A 2.4-year average diagnostic delay, plus 200 to 400 patients a year undertreated at non-PNH centres, accounts for most of that gap. MSM · GCC GCC IgA Nephropathy Market Sizing Model A GCC nephrology network capacity survey estimates 8,000-12,000 IgA nephropathy patients across the region. The same survey finds kidney biopsy performed in fewer than 30% of eligible proteinuric patients, and zero patients on any SFDA-registered novel agent as of 2024. LR · US US Atopic Dermatitis Launch Readiness Dupilumab's 70% share sets the biologic entrenchment bar. The 2022 JAK boxed warning sets a second, harder gate for any oral entrant. LR · US US Obesity Launch Readiness Wegovy and Zepbound already occupy the injectable position. A new entrant must clear the 20.9% efficacy bar and price beneath the $274 IRA reset arriving in 2027. MSM · UK UK IgA Nephropathy Market Sizing Model The UK Renal Registry tracks about 8,000 IgA nephropathy patients against an estimated 10,000-15,000 total prevalence. Only 3,000-5,000 are eligible for a novel agent, and fewer than 500 currently receive one. MSM · US US Pompe Disease Market Sizing Model US Pompe prevalence runs 5,000 to 10,000 patients, 70-80% late-onset. Of the roughly 2,000 LOPD patients on enzyme replacement therapy, 375 to 600 are inadequate responders, the addressable population any new agent must reach. MSM · UK UK Fabry Disease Market Sizing Model 700-900 diagnosed UK Fabry patients split roughly 600 on ERT to 200 on oral therapy. Two niches sit inside that: 50-80 ADA-positive suboptimal responders and 80-120 undertreated symptomatic female heterozygotes, against a £144M NHS spend anchor. P&HTA · GCC GCC Dravet Syndrome Payer & HTA The most effective Dravet agent is the least accessible in the GCC. Cannabidiol's Schedule-1-equivalent narcotics classification caps exceptional-import approval at 35-40%. MSM · US US Sickle Cell Disease Market Sizing Model A ~100,000-patient US SCD population narrows to a 55,000-65,000-patient addressable white space. Only 50-100 gene-therapy patients were actually treated in the first 12 months, versus 200-300 projected. MSM · US US ATTR Amyloidosis Market Sizing Model An estimated 500,000+ US patients aged 70+ have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated. A separate 100,000+ Val122Ile hereditary carrier pool sits alongside it. CI · UK UK Pompe Disease Competitive Intelligence Avalglucosidase alfa's NICE recommendation (TA821) puts it against entrenched alglucosidase alfa. NHS switch criteria and the Pombiliti queue position define the next 18 months of UK access.